VYGR insider buying and SEC filings, explained
Voyager Therapeutics, Inc. · CIK 1640266
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$77K
Planned sales (10b5-1)
$221K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Apr 2, 2026 | Planned (10b5-1) | Alfred Sandrock (CEO and Director) sold 11,511 shares at about $3.87 ($45K), marked as a 10b5-1 plan trade. Holdings down 2% to 472,549 shares. | SEC filing Filed Apr 3, 2026 |
| Feb 24, 2026 | Planned (10b5-1) | Robin Swartz (President / COO) sold 6,458 shares at about $3.77 ($24K), marked as a 10b5-1 plan trade. Holdings down 3% to 199,738 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 24, 2026 | Planned (10b5-1) | Alfred Sandrock (CEO and Director) sold 14,197 shares at about $3.79 ($54K), marked as a 10b5-1 plan trade. Holdings down 3% to 484,060 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 24, 2026 | Planned (10b5-1) | Nathan D. Jorgensen (CFO) sold 4,668 shares at about $3.77 ($18K), marked as a 10b5-1 plan trade. Holdings down 3% to 151,416 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 24, 2026 | Planned (10b5-1) | Todd Alfred Carter (Chief Scientific Officer) sold 4,174 shares at about $3.76 ($16K), marked as a 10b5-1 plan trade. Holdings down 3% to 145,718 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Robin Swartz (President / COO) sold 3,882 shares at about $3.44 ($13K), marked as a 10b5-1 plan trade. Holdings down 2% to 206,196 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Todd Alfred Carter (Chief Scientific Officer) sold 3,301 shares at about $3.44 ($11K), marked as a 10b5-1 plan trade. Holdings down 2% to 149,892 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Alfred Sandrock (CEO and Director) sold 11,732 shares at about $3.41 ($40K), marked as a 10b5-1 plan trade. Holdings down 2% to 498,257 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 10, 2026 | Sale | Robin Swartz (President / COO) sold 4,569 shares at about $3.85 ($18K). Holdings down 2% to 210,078 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 10, 2026 | Sale | Alfred Sandrock (CEO and Director) sold 12,192 shares at about $3.78 ($46K). Holdings down 2% to 509,989 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
| Feb 10, 2026 | Sale | Todd Alfred Carter (Chief Scientific Officer) sold 3,525 shares at about $3.85 ($14K). Holdings down 2% to 153,193 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
18 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow VYGR in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.